ClinicalTrials.gg
CompletedNCT02918968Updated Dec 9, 2024Results posted

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

A Phase 4 interventional study of Enzalutamide and Flutamide in Prostate Cancer, sponsored by Astellas Pharma Inc. Completed at 47 sites in Japan. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
27th of 125
206 · median 52
Started
2016
with 8 others
Phase 4
7 of 125
none open now
Registered
69th of 125
by date
Lead sponsor
7 of 125
Astellas Pharma Inc

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 27th largest by enrollment, is one of 9 that started in 2016, is one of 7 in phase 4, and was the 69th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration resistant prostate cancer who had relapsed during combined androgen blockade (CAB) therapy with bicalutamide and ADT. This study also investigated the order of alternative antiandrogen therapy (AAT) by changing the 1st line medication after relapse of prostate-specific antigen (PSA).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • enzalutamide
  • Xtandi
  • Prostate Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is diagnosed with or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small-cell histology.
  • Subject on continuous ADT with Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or bilateral orchiectomy.
  • Serum testosterone level below the target level at screening visit.
  • Subject with asymptomatic or mildly symptomatic prostate cancer.
  • Subject has an (ECOG) performance status of 0 or 1.
  • Subject has progression of the disease as defined by rising PSA levels or progressive soft tissue or bony disease during CAB therapy in combination of bicalutamide and ADT.
  • A sexually active male subject and the subject's female partner who is of must use 2 acceptable methods from screening to 3 months after the last dose of the study drug.
  • Subject must agree not to donate sperm from screening to 3 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Subject with severe concurrent diseases, infections, or complications.
  • Subject with confirmed or suspected or active .
  • Subject with a history of malignant tumor other than prostate cancer in the past 5 years.
  • Subject hypersensitive to the ingredients of enzalutamide capsules or flutamide tablets.
  • Subject with a history of convulsive attack, or prone to convulsive attack.
  • Subject with liver disorder such as viral hepatitis and hepatic cirrhosis, or subject with (AST) and Alanine aminotransferase (ALT) at screening visit higher than the .
  • Subject received treatment for prostate cancer with cytocidal chemotherapy that includes anti androgenic agents other than bicalutamide, abiraterone, or estramustine.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT

    Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).

    Drug: Enzalutamide · Drug: Flutamide · Other: Androgen deprivation therapy

  • Experimental
    Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT

    Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).

    Drug: Enzalutamide · Drug: Flutamide · Other: Androgen deprivation therapy

Interventions

  • Oral Capsule

    Also known as: Xtandi, MDV3100

  • Oral tablet

  • OtherAndrogen deprivation therapy

    All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.

06

What researchers measure

Primary outcomes

  1. Time to PSA Progression With 1st Line AAT (TTPP1)

    TTPP1 was defined as the period from the date of randomization to the date of PSA progression in the 1st line AAT period. PSA progression was defined according to the consensus guidelines of prostate cancer clinical trials working group 2 (PCWG2). For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier (KM) estimates.

    Time frame: From date of randomization to the date of PSA progression in the 1st line AAT period (Up to 38 months)

Secondary outcomes

  1. Time to PSA Progression With 2nd Line AAT (TTPP2)

    TTPP2 was defined as the period from day 1 of the 2nd line AAT to the date of PSA progression with the 2nd line AAT. PSA progression was defined according to the consensus guidelines of PCWG2. For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier estimates.

    Time frame: From date of randomization to the date of PSA progression in 2nd line AAT (Up to 38 months)

  2. Percentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline and Up To Week 38 in Prostate Specific Antigen (PSA) Response at 1st Line AAT

    PSA response was defined as PSA decreased by at least 50% or 90% from baseline when at least 3 weeks passed after the lowest PSA decreased by at least 50% or 90% from baseline in the 1st line AAT period after baseline. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

    Time frame: Baseline and at least 3 weeks after, the lowest PSA decreased by at least 50% or 90% from baseline (Up to 38 months)

  3. Percentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline to Week 13 in Prostate Specific Antigen (PSA) Response at 1st Line AAT

    PSA response was defined as the lowest PSA at week 13 decreased by at least 50% or 90% from baseline in the 1st line AAT period. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

    Time frame: Baseline and week 13

  4. Time to PSA Decrease by 50% From Baseline With 1st Line AAT

    Time to PSA decrease by 50% with 1st line AAT was defined as the period from the date of randomization to the day when the decrease of PSA from baseline by 50% is first identified. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

    Time frame: From date of randomization to the day when the decrease of PSA from baseline by 50% is first identified (Up to 38 months)

  5. Time to Treatment Failure of 1st Line AAT (TTF1)

    TTF1 was defined as the period from randomization to study drug discontinuation of 1st line AAT for any reason that includes disease progression, onset of adverse events (AEs), participants request, or death. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

    Time frame: From date of randomization to discontinuation of 1st line AAT (Up to 38 months)

  6. Time to Treatment Failure of 2nd Line AAT (TTF2)

    TTF2 was defined as the period from randomization to study drug discontinuation of 2nd line AAT for any reason that includes disease progression, onset of AEs, participants request, or death. Time to event analysis was performed using kaplan-meier estimates.

    Time frame: From date of randomization to discontinuation of 2nd line AAT (Up to 38 months)

  7. Radiographic Progression-free Survival (rPFS)

    rPFS was defined as the period from randomization to the time when radiographic disease progression is observed or death of any cause during the study period, whichever occurs earlier. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

    Time frame: From date of randomization to the time when radiographic disease progression is observed or death of any cause (up to 38 months)

07

Results

Posted May 21, 2021

Participant flow

Participants with M0 or M1 castration-resistant prostatic neoplasm that relapsed during Combined Androgen Blockade (CAB) therapy with bicalutamide were enrolled in this study.

1st Line AAT
Participant flow — 1st Line AAT
MilestoneEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
Started102104
Maintained 1st line aat without progression258
Completed7393
Not completed2911
Withdrew: Progressive disease94
Withdrew: Adverse event123
Withdrew: Physician decision42
Withdrew: Withdrawal by subject21
Withdrew: Lost to follow-up01
Withdrew: Death10
Withdrew: Miscellaneous10
2nd Line AAT
Participant flow — 2nd Line AAT
MilestoneEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
Started4885
Completed2373
Not completed2512
Withdrew: Progressive disease213
Withdrew: Adverse event25
Withdrew: Physician decision01
Withdrew: Withdrawal by subject22
Withdrew: Death01

Outcome measures

PrimaryTime to PSA Progression With 1st Line AAT (TTPP1)

TTPP1 was defined as the period from the date of randomization to the date of PSA progression in the 1st line AAT period. PSA progression was defined according to the consensus guidelines of prostate cancer clinical trials working group 2 (PCWG2). For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier (KM) estimates.

Time frame:
From date of randomization to the date of PSA progression in the 1st line AAT period (Up to 38 months)
Reported as:
Median · Months
Time to PSA Progression With 1st Line AAT (TTPP1)
MonthsEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
Time to PSA Progression With 1st Line AAT (TTPP1)21.39 (12.16 to NA)5.78 (4.67 to 8.54)
Statistical analysis
  • Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT vs Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT · Log Rank · p = <0.001 (P-value is based on a log-rank test stratified disease stages (M0/N0, M0/N1, or M1).) · Hazard ratio (hr): 0.42 · 95% CI 0.29 to 0.61Hazard ratio and P-value calculated using unstratified Cox proportional hazards model with treatment and disease stages (M0/N0, M0/N1, or M1) as covariate.
SecondaryTime to PSA Progression With 2nd Line AAT (TTPP2)

TTPP2 was defined as the period from day 1 of the 2nd line AAT to the date of PSA progression with the 2nd line AAT. PSA progression was defined according to the consensus guidelines of PCWG2. For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier estimates.

Time frame:
From date of randomization to the date of PSA progression in 2nd line AAT (Up to 38 months)
Reported as:
Median · Months
Time to PSA Progression With 2nd Line AAT (TTPP2)
MonthsEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
Time to PSA Progression With 2nd Line AAT (TTPP2)NA (20.99 to NA)21.22 (14.78 to NA)
SecondaryPercentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline and Up To Week 38 in Prostate Specific Antigen (PSA) Response at 1st Line AAT

PSA response was defined as PSA decreased by at least 50% or 90% from baseline when at least 3 weeks passed after the lowest PSA decreased by at least 50% or 90% from baseline in the 1st line AAT period after baseline. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

Time frame:
Baseline and at least 3 weeks after, the lowest PSA decreased by at least 50% or 90% from baseline (Up to 38 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline and Up To Week 38 in Prostate Specific Antigen (PSA) Response at 1st Line AAT
Percentage of participantsEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
M0/N0: (≥ 50% reduction)75.0 (53.3 to 90.2)48.0 (27.8 to 68.7)
M0/N1: (≥ 50% reduction)66.7 (9.4 to 99.2)0.0 (0.0 to 60.2)
M1: (≥ 50% reduction)72.0 (60.4 to 81.8)32.0 (21.7 to 43.8)
All participants: (≥ 50% reduction)72.5 (62.8 to 80.9)34.6 (25.6 to 44.6)
M0/N0: (≥ 90% reduction)62.5 (40.6 to 81.2)8.0 (1.0 to 26.0)
M0/N1: (≥ 90% reduction)33.3 (0.8 to 90.6)0.0 (0.0 to 60.2)
M1: (≥ 90% reduction)53.3 (41.4 to 64.9)20.0 (11.6 to 30.8)
All participants: (≥ 90% reduction)54.9 (44.7 to 64.8)16.3 (9.8 to 24.9)
Statistical analysis
  • Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT vs Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT · Mantel Haenszel · p = <0.001 (P-value is based on Cochran-Mantel-Haenszel mean score test stratified disease stages (M0/N0, M0/N1, or M1).) · Risk difference (rd): 37.8 · 95% CI 25.2 to 50.4Difference of response rate.
  • Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT vs Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT · Mantel Haenszel · p = <0.001 (P-value is based on Cochran-Mantel-Haenszel mean score test stratified disease stages (M0/N0, M0/N1, or M1).) · Risk difference (rd): 38.4 · 95% CI 26.3 to 50.4Difference of response rate
SecondaryPercentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline to Week 13 in Prostate Specific Antigen (PSA) Response at 1st Line AAT

PSA response was defined as the lowest PSA at week 13 decreased by at least 50% or 90% from baseline in the 1st line AAT period. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

Time frame:
Baseline and week 13
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline to Week 13 in Prostate Specific Antigen (PSA) Response at 1st Line AAT
Percentage of participantsEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
M0/N0: (≥ 50% reduction)83.3 (62.6 to 95.3)40.0 (21.1 to 61.3)
M0/N1: (≥ 50% reduction)66.7 (9.4 to 99.2)0.0 (0.0 to 60.2)
M1: (≥ 50% reduction)72.0 (60.4 to 81.8)33.3 (22.9 to 45.2)
All participants: (≥ 50% reduction)74.5 (64.9 to 82.6)33.7 (24.7 to 43.6)
M0/N0: (≥ 90% reduction)50.0 (29.1 to 70.9)8.0 (1.0 to 26.0)
M0/N1: (≥ 90% reduction)33.3 (0.8 to 90.6)0.0 (0.0 to 60.2)
M1: (≥ 90% reduction)49.3 (37.6 to 61.1)18.7 (10.6 to 29.3)
All participants: (≥ 90% reduction)49.0 (39.0 to 59.1)15.4 (9.1 to 23.8)
Statistical analysis
  • Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT vs Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT · Mantel Haenszel · p = <0.001 (P-value is based on Cochran-Mantel-Haenszel mean score test stratified disease stages (M0/N0, M0/N1, or M1).) · Risk difference (rd): 40.7 · 95% CI 28.3 to 53.1Difference of response rate.
  • Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT vs Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT · Mantel Haenszel · p = <0.001 (P-value is based on Cochran-Mantel-Haenszel mean score test stratified disease stages (M0/N0, M0/N1, or M1).) · Risk difference (rd): 33.5 · 95% CI 21.5 to 45.4Difference of response rate
SecondaryTime to PSA Decrease by 50% From Baseline With 1st Line AAT

Time to PSA decrease by 50% with 1st line AAT was defined as the period from the date of randomization to the day when the decrease of PSA from baseline by 50% is first identified. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

Time frame:
From date of randomization to the day when the decrease of PSA from baseline by 50% is first identified (Up to 38 months)
Reported as:
Median · Months
Time to PSA Decrease by 50% From Baseline With 1st Line AAT
MonthsEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
M0/N02.79 (2.66 to 3.02)3.94 (2.79 to NA)
M0/N12.79 (2.56 to NA)NA (NA to NA)
M12.79 (NA to NA)7.49 (3.02 to NA)
Statistical analysis
  • Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT vs Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT · Log Rank · p = <0.001 (P-value is based on a log-rank test stratified disease stages (M0/N0, M0/N1, or M1).)
SecondaryTime to Treatment Failure of 1st Line AAT (TTF1)

TTF1 was defined as the period from randomization to study drug discontinuation of 1st line AAT for any reason that includes disease progression, onset of adverse events (AEs), participants request, or death. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

Time frame:
From date of randomization to discontinuation of 1st line AAT (Up to 38 months)
Reported as:
Median · Months
Time to Treatment Failure of 1st Line AAT (TTF1)
MonthsEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
M0/N017.58 (10.15 to 24.11)7.72 (4.47 to 15.67)
M0/N15.55 (4.86 to 10.38)4.73 (1.87 to 7.62)
M112.02 (7.39 to 18.43)3.94 (3.65 to 5.55)
Statistical analysis
  • Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT vs Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT · Log Rank · p = <0.001 (P-value is based on a log-rank test stratified disease stages (M0/N0, M0/N1, or M1).)
SecondaryTime to Treatment Failure of 2nd Line AAT (TTF2)

TTF2 was defined as the period from randomization to study drug discontinuation of 2nd line AAT for any reason that includes disease progression, onset of AEs, participants request, or death. Time to event analysis was performed using kaplan-meier estimates.

Time frame:
From date of randomization to discontinuation of 2nd line AAT (Up to 38 months)
Reported as:
Median · Months
Time to Treatment Failure of 2nd Line AAT (TTF2)
MonthsEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
Time to Treatment Failure of 2nd Line AAT (TTF2)23.03 (16.79 to NA)16.59 (13.14 to 23.95)
SecondaryRadiographic Progression-free Survival (rPFS)

rPFS was defined as the period from randomization to the time when radiographic disease progression is observed or death of any cause during the study period, whichever occurs earlier. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

Time frame:
From date of randomization to the time when radiographic disease progression is observed or death of any cause (up to 38 months)
Reported as:
Median · Months
Radiographic Progression-free Survival (rPFS)
MonthsEnzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT
M1NA (NA to NA)NA (29.08 to NA)
Statistical analysis
  • Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT vs Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT · Log Rank · p = 0.669 (P-value is based on a log-rank test stratified disease stages (M0/N0, M0/N1, or M1)) · Hazard ratio (hr): 0.87 · 95% CI 0.45 to 1.67Hazard ratio and P-value calculated using unstratified Cox proportional hazards model with treatment and disease stages (M0/N0, M0/N1, or M1) as covariate.

Adverse events

Collected over From of date of randomization to end of study (up to 38 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide 160mg 1st Line AAT1/102 (1%)29/102 (28.4%)79/102 (77.5%)
Enzalutamide 160mg 2nd Line AAT1/85 (1.2%)18/85 (21.2%)56/85 (65.9%)
Flutamide 375mg 1st Line AAT0/104 (0%)15/104 (14.4%)65/104 (62.5%)
Flutamide 375mg 2nd Line AAT0/48 (0%)4/48 (8.3%)22/48 (45.8%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventEnzalutamide 160mg 1st Line AATEnzalutamide 160mg 2nd Line AATFlutamide 375mg 1st Line AATFlutamide 375mg 2nd Line AAT
Cerebral infarctionNervous system disorders3/1020/851/1040/48
Large intestine polypGastrointestinal disorders0/1022/850/1040/48
Hepatic function abnormalHepatobiliary disorders1/1022/851/1040/48
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1022/850/1040/48
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1022/850/1040/48
Cardiac failureCardiac disorders0/1020/850/1041/48
Ileus paralyticGastrointestinal disorders0/1020/850/1041/48
Loss of consciousnessNervous system disorders1/1020/850/1041/48
DeliriumPsychiatric disorders0/1021/850/1041/48
Acute kidney injuryRenal and urinary disorders1/1020/850/1041/48
Most frequent other events
Showing 10 of 21
Most frequent other events
EventEnzalutamide 160mg 1st Line AATEnzalutamide 160mg 2nd Line AATFlutamide 375mg 1st Line AATFlutamide 375mg 2nd Line AAT
NasopharyngitisInfections and infestations23/10212/8517/1042/48
MalaiseGeneral disorders15/10217/854/1042/48
FallInjury, poisoning and procedural complications18/10210/854/1041/48
FatigueGeneral disorders15/1028/853/1040/48
Back painMusculoskeletal and connective tissue disorders15/1024/856/1041/48
ConstipationGastrointestinal disorders14/1022/853/1040/48
HypertensionVascular disorders13/1025/852/1040/48
DiarrhoeaGastrointestinal disorders7/1022/8512/1046/48
Decreased appetiteMetabolism and nutrition disorders11/1028/854/1042/48
Hepatic function abnormalHepatobiliary disorders2/1022/859/1042/48

Baseline characteristics

Intent-to-Treat (ITT) population was defined as all participants randomized in this study.

Age, Continuous
Age, Continuous(years)Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AATTotal
Mean74.4 ± 7.674.1 ± 7.674.2 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AATTotal
Female000
Male102104206
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AATTotal
Count of participants——0
Disease Stages at Randomization
Disease Stages at Randomization(Participants)Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AATFlutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AATTotal
M0/N0242549
M0/N1347
M17575150
08

Study locations

47 sites
  • Site JP00024
    Nagoya, Aichi, Japan
  • Site JP00025
    Nagoya, Aichi, Japan
  • Site JP00038
    Matsuyama, Ehime, Japan
  • Site JP00051
    Iizuka, Fukuoka, Japan
  • Site JP00045
    Isesaki, Gunma, Japan
  • Site JP00005
    Maebashi, Gunma, Japan
  • Site JP00043
    Ota, Gunma, Japan
  • Site JP00054
    Hakodate, Hokkaido, Japan
  • Site JP00001
    Sapporo, Hokkaido, Japan
  • Site JP00002
    Sapporo, Hokkaido, Japan
  • Site JP00048
    Sapporo, Hokkaido, Japan
  • Site JP00055
    Mito, Ibaraki, Japan
  • Site JP00019
    Sagamihara, Kanagawa, Japan
  • Site JP00020
    Yokohama, Kanagawa, Japan
  • Site JP00021
    Yokohama, Kanagawa, Japan
  • Site JP00044
    Yokosuka, Kanagawa, Japan
  • Site JP00046
    Kashihara, Nara, Japan
  • Site JP00033
    Kurashiki, Okayama, Japan
  • Site JP00028
    Hirakata, Osaka, Japan
  • Site JP00030
    Osakasayama, Osaka, Japan
  • Site JP00027
    Suita, Osaka, Japan
  • Site JP00009
    Kitaadachi-gun, Saitama, Japan
  • Site JP00022
    Hamamatsu, Shizuoka, Japan
  • Site JP00049
    Utsunomiya, Tochigi, Japan
  • Site JP00011
    Bunkyo-ku, Tokyo, Japan
  • Site JP00017
    Bunkyo-ku, Tokyo, Japan
  • Site JP00013
    Koto-ku, Tokyo, Japan
  • Site JP00014
    Nakano-ku, Tokyo, Japan
  • Site JP00016
    Shinagawa-ku, Tokyo, Japan
  • Site JP00018
    Shinjuku-ku, Tokyo, Japan
  • Site JP00034
    Ube, Yamaguchi, Japan
  • Site JP00010
    Chiba, Japan
  • Site JP00053
    Chiba, Japan
  • Site JP00039
    Fukuoka, Japan
  • Site JP00040
    Fukuoka, Japan
  • Site JP00050
    Fukuoka, Japan
  • Site JP00035
    Hiroshima, Japan
  • Site JP00026
    Kyoto, Japan
  • Site JP00006
    Nagano, Japan
  • Site JP00008
    Nagano, Japan
  • Site JP00041
    Nagasaki, Japan
  • Site JP00029
    Osaka, Japan
  • Site JP00031
    Osaka, Japan
  • Site JP00032
    Osaka, Japan
  • Site JP00042
    Saga, Japan
  • Site JP00037
    Tokushima, Japan
  • Site JP00052
    Toyama, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2020, 40 months.

Results were first posted in May 2021, 1 year 1 month after primary completion.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2016
First posted
Sep 29, 2016
StartActual
Nov 2, 2016
Primary completionActual
Mar 27, 2020
CompletionActual
Mar 27, 2020
Results first posted
May 21, 2021
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02918968
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Sep 29, 2016
Start date
Nov 2, 2016
Primary completion
Mar 27, 2020
Completion
Mar 27, 2020
Results posted
May 21, 2021
Last update
Dec 9, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enzalutamide · Flutamide

Start the discussion